LGX818 for Patients With BRAFV600 Mutated Tumors

NCT01981187 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Due to slow enrollment and lack of response observed during the enrollment period, the Sponsor decided to close study enrollment early on 28 January 2015

Conditions

Solid Tumor
Hematologic Malignancies

Interventions

DRUG: LGX818

Sponsor

Pfizer